Technology Appraisal no 181; Pemetrexed for the first-line treatment of non-small-cell lung cancer

Whilst considering a proposal for a review of TA181, NICE  became aware of an independent Health Technology Assessment (HTA) report on First-line therapy for adult patients with non-small-cell lung cancer  currently being compiled by the Liverpool Review and Implementation Group (LRiG), Liverpool University.  This HTA is anticipated to publish in mid 2011. 

The results of the HTA report may have a significant impact upon the consideration to review TA181.   Consequently Guidance Executive has decided that the consideration to review the original guidance will be deferred until mid 2011 to coincide with publication of the Health Technology Assessment.  At this point the evidence base will again be assessed to ascertain the need for a review of the guidance.

May 2011